CAMBRIDGE, Mass. (
announced significant job cuts late Thursday after its partner
said it was ending a five-year research partnership focused on gene silencing drugs.
The layoffs at Alnylam will encompass about 25-30% of the company's workforce that will cost the company about $3 million, most of which will be charged in the third quarter. Alnylam reaffirmed its cash guidance to end the year with more than $325 million in cash.
Alnylam is a developer of drugs based RNA interference, or RNAi, which uses snippets of genetic material to turn off genes that cause disease.
Novartis and Alnylam signed a three-year research partnership in 2005 that was extended until the end of 2010. On Thursday, Novartis informed Alnylam that the course of the collaboration was ending after Novartis chose 31 drug targets for further development. These drug targets are based on Alnylam's RNAi research and technology, which makes the company eligible for future milestones and royalties if Novartis successfully develops the targets into real drugs.
Internally, Alnylam's lead RNAi drug is RSV-101 in phase II studies for respiratory syncytial virus, a serious lung infection that mainly affects premature babies and people with compromised immune systems. Cubist Pharmaceuticals is Alnylam's development partner for RSV-101.
Alnylam has a liver cancer drug, ALN-VSP, in phase I development.
Alnylam shares closed Thursday at $14.22.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.